The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT Purpose Male breast cancer (MBC) is underrepresented in cancer statistics: this study aimed to assess the burden of MBC in Central, Eastern, and Western Europe from 1990 to 2023, using data from the Global Burden of Disease (GBD) Study 2023. Methods Estimates from GBD 2023 were analyzed to determine the MBC incidence, mortality, and disability‐adjusted life years, their all‐ages and age‐standardized rates, and the 1990 through 2023 annual percent change. These estimates were compared to those for the GBD Super Regions and the Socio‐Demographic Index quintile countries. Results In Central Europe, age‐standardized incidence rates (ASIR) increased from 0.54 (0.40–0.76) to 1.05 (0.70–1.52), age‐standardized mortality rates (ASMR) from 0.29 (0.25–0.34) to 0.40 (0.36–0.45), and age‐standardized disability life‐year rates (ASDR) from 7.19 (6.15–8.41) to 9.63 (8.52–11.07). In Eastern Europe, ASIR remained relatively stable, changing from 0.81 (0.56–1.19) to 0.60 (0.38–0.92), whereas ASMR decreased from 0.40 (0.33–0.49) to 0.21 (0.16–0.25) and ASDR from 10.54 (8.69–12.89) to 5.55 (4.52–6.85). In Western Europe, ASIR increased from 0.47 (0.33–0.67) to 0.88 (0.59–1.24), whereas ASMR (0.22 [0.19–0.25] vs. 0.24 [0.21–0.27]) and ASDR (5.20 [4.49–5.97] vs. 5.75 [4.96–6.66]) remained stable. Conclusions The burden of MBC is increasing across Europe, particularly in the Central region, with huge regional differences. Population growth and variations over time impacted on the metrics. Even with a composite European scenario, the mortality‐to‐incidence ratio markedly declined in the three areas.